Regeneron secures approval for ultra-rare bone disorder drug
Regeneron's therapy for an ultra-rare condition that causes abnormal bone formation has received U.S. regulatory approval. The decision ends a three-decade-long development effort for the company.
Related stories
Regeneron wins FDA approval for first treatment of rare bone-forming disease · Drug development
J&J's Imaavy becomes first approved therapy for rare anemia · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more.” Browse more stories.